Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01534650 · ClinicalTrials.gov registry record
Movement Disorder Quantification Algorithm Development
A clinical trial, sponsored by Great Lakes NeuroTechnologies.
- Completed
- Registry status
- 17
- Enrollment target
NCT01534650: Completed study, sponsored by Great Lakes NeuroTechnologies.
NCT01534650 is a clinical trial that has completed, run by Great Lakes NeuroTechnologies. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01534650 has completed, sponsored by Great Lakes NeuroTechnologies.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such as tremor, bradykinesia (slowed movements), dyskinesias (sudden, involuntary movements), gait, and balance during standardized tasks and/or activities of daily living.
Primary Outcome
Motion data collected during various motor tasks will be processed and compared to video review.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-01 |
What the finished NCT01534650 record still lists
NCT01534650 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01534650 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01534650 about?
NCT01534650 is a clinical study titled "Movement Disorder Quantification Algorithm Development". The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such as tremor, bradykinesia (slowed movements), dyskinesias (sudden, invol...
What is the current status of trial NCT01534650?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2012-02. Estimated completion is 2016-01.
Who is sponsoring clinical trial NCT01534650?
This trial is sponsored by Great Lakes NeuroTechnologies, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia